← Eichor
Study identifier: NCT05440227 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

Condition: Cancer-related Fatigue  ·  Sponsor: PhytoHealth Corporation

PhasePhase 2
Planned participants36
Who can joinFemale, 20 Years to no upper limit
Healthy volunteersNo

About this study

The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies.

This description comes directly from the study's public registry record.

Talk to the study team

Tim Teng-Hsu Wang, PhD  ·  +886 2 2545-3697  ·  tim.wang@phytohealth.com.tw

Always discuss trial participation with your own doctor first.

Locations (1)

National Taiwan University HospitalTaipei, TaiwanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05440227